It appears that Washington is about to enact sweeping legislation that will be the greatest shift in public policy in decades. Yes, we can bemoan the lack of a completely private enterprise driven system but the reality is Big Brother is here and he's not going away. Without a doubt there will be implications for investors that need to be considered; and it's not all bad news from an investment perspective.   Read More

Stacy and Clinton definitely had nothing to do with it, but Sanofi-Pasteur (the vaccines division of Sanofi-Aventis) greets visitors with a "What Not To Wear" brochure.    Read More

Maybe even higher, the Mad Money host says. Plus, find out which team’s win of the World Series is better for the markets.   Read More

I am not a Trekkie. In fact, sci-fi and fantasy are two of of my least favorite genres. But the Vulcan salutation was one of the first things I thought of when I went to the facelifted Merck Web site this morning to link to and print the press release about the new Merck.    Read More

Plus, get seven more names to buoy your portfolio when the previously mentioned eight aren’t working.   Read More

Pfizer, or one of its ad agencies, is apparently putting out a casting call for a new Lipitor pitchman.   Read More

Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma. First the bad news.    Read More

It’s time to readjust your portfolio, the Mad Money host says. Start with these companies.   Read More

I end the week as I started it: blogging about Vivus and the three-contestant race to make a new prescription diet pill.    Read More

On a day when the market is in full-tilt rally mode on the GDP number, shares of Dow component Merck and the company it's buying, Schering-Plough, are sliding. So, what gives?    Read More